DavidBruceKudrowMD

Headache

Director, California Medical Clinic for Headache. Director, Headache Clinic Harbor-UCLA Medical Center. Assistant Clinical Professor in Neurology UCLA David Geffen School of Medicine.

Join to view full profile

Dr. Kudrow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kudrow's full profile

Already have an account?

Office
2080 Century Park East
Suite 805
Century City, CA 90067
Phone+1 310-315-1456

Fax+1 310-315-1486

Summary

Dr. David Kudrow is a neurologist in Century City, CA and is affiliated with Providence Saint John's Health Center. He received his medical degree from University of Southern California School of Medicine and has been in practice 35 years. He specializes in headache and is experienced in migraine disorders and headache disorders.

Education & Training

Los Angeles County-Harbor-UCLA Medical CenterResidency, Neurology, 1987 - 1991
UCLA-VA Greater Los AngelesInternship, Internal Medicine, 1986 - 1987
Keck School of Medicine of the University of Southern CaliforniaClass of 1986

Certifications & Licensure

IL State Medical License 2019 - 2026
MT State Medical License 2020 - 2026
NY State Medical License 2018 - 2026
TX State Medical License 2020 - 2026
UT State Medical License 2019 - 2026
AZ State Medical License 2021 - 2025
CA State Medical License 1988 - 2025
CO State Medical License 2020 - 2025
FL State Medical License 2019 - 2025
WA State Medical License 2020 - 2025
WY State Medical License 2021 - 2025
HI State Medical License 1995 - 1996
American Board of Psychiatry and Neurology Neurology
Join now to see all

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine. Start of enrollment: 2005 Dec 01
Completed
Phase 2
Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine Start of enrollment: 2008 Apr 01
Completed
Not Applicable
Preventive Treatment of Episodic and Chronic Migraine Start of enrollment: 2011 Apr 01
Unknown status
Phase 4
Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve Start of enrollment: 2014 Mar 01
Terminated
Phase 2
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension Start of enrollment: 2013 Oct 01
Completed
Phase 3
The Nutritional Benefits of Metanx in Patients With Diabetic Peripheral Neuropathy (MEDIAN) Start of enrollment: 2013 Nov 01
Unknown status
Not Applicable
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects Start of enrollment: 2013 Dec 01
Completed
Phase 2, Phase 3
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache Start of enrollment: 2014 Jul 07
Completed
Phase 2
A Study of Galcanezumab in Participants With Chronic Cluster Headache Start of enrollment: 2015 Jun 18
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study.
David Kudrow, Susan Hutchinson, Glenn C Pixton, Terence Fullerton
Pain and Therapy. 2024-11-09
Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache.
Andrew Blumenfeld, David Kudrow, Peter McAllister, Line Pickering Boserup, Joe Hirman
Headache. 2024-06-24
11 citations
A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Alexandra Thiry
Cephalalgia. 2024-04-01

Press Mentions

Long-Term Safety and Tolerability of Eptinezumab in Patients with Chronic Migraine: A 2-Year, Open-Label, Phase 3 TrialMarch 19th, 2021
FDA Approves Galcanezumab-Gnlm for Episodic Cluster HeadacheJune 5th, 2019
Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual MeetingApril 23rd, 2019
Join now to see all